Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dhanvanthri S Deevi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Experimental Therapeutics & Oncology|December 4, 2003
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculataSriram Rajagopal, R Ajaya Kumar, Dhanvanthri S Deevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyJames R Tonra, Dhanvanthri S Deevi, Erik Corcoran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximabMarie Prewett, Dhanvanthri S Deevi, Rajiv Bassi, et al.
Cancer Genomics & Proteomics|March 9, 2012
Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLCSelda Samakoglu, Dhanvanthri S Deevi, Huiling Li, et al.
Anticancer Research|June 17, 2009
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer modelsJames R Tonra, Erik Corcoran, Dhanvanthri S Deevi, et al.
Vaccines|July 27, 2024
Development of a Cell-Based Reporter Potency Assay for Live Virus VaccinesDengyun Sun, Brian K Meyer, Dhanvanthri S Deevi, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Biological investigation and structure-activity relationship studies on azadirone from Azadirachta indica A. JussSrinivas Nanduri, Siva Sanjeeva Rao Thunuguntla, Vijay Kumar Nyavanandi, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agentsVedula M Sharma, K V Adi Seshu, C Vamsee Krishna, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitorsYong-Jiang Xu, Hua-Quan Miao, Weitao Pan, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibodyJuqun Shen, Marie Danielle Vil, Marie Prewett, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Experimental Therapeutics & Oncology|December 4, 2003
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculataSriram Rajagopal, R Ajaya Kumar, Dhanvanthri S Deevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapyJames R Tonra, Dhanvanthri S Deevi, Erik Corcoran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximabMarie Prewett, Dhanvanthri S Deevi, Rajiv Bassi, et al.
Cancer Genomics & Proteomics|March 9, 2012
Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLCSelda Samakoglu, Dhanvanthri S Deevi, Huiling Li, et al.
Anticancer Research|June 17, 2009
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer modelsJames R Tonra, Erik Corcoran, Dhanvanthri S Deevi, et al.
Vaccines|July 27, 2024
Development of a Cell-Based Reporter Potency Assay for Live Virus VaccinesDengyun Sun, Brian K Meyer, Dhanvanthri S Deevi, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Biological investigation and structure-activity relationship studies on azadirone from Azadirachta indica A. JussSrinivas Nanduri, Siva Sanjeeva Rao Thunuguntla, Vijay Kumar Nyavanandi, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agentsVedula M Sharma, K V Adi Seshu, C Vamsee Krishna, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitorsYong-Jiang Xu, Hua-Quan Miao, Weitao Pan, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibodyJuqun Shen, Marie Danielle Vil, Marie Prewett, et al.
Pageof 2